Patient characteristics
| Patient characteristics . | N = 178 (%) . |
|---|---|
| Female | 77 (43.3) |
| Age (y), median (range) | 66 (17-94) |
| Stage at diagnosis∗ | |
| Stage IVA1 | 139 (82.3) |
| Stage IVA2 | 26 (15.4) |
| Stage IVB | 4 (2.4) |
| Coexistent large cell transformation at time of diagnosis with SS | 35 (20.0) |
| Prior history of MF without B2 blood involvement | 48 (27.0) |
| Number of prior lines of therapy for MF, median (range) | 2 (0-9) |
| Number of treatment lines for SS, median (range) | 4 (1-16) |
| Number of lines of systemic therapies for SS, median (range) | 3 (0-14) |
| Patient characteristics . | N = 178 (%) . |
|---|---|
| Female | 77 (43.3) |
| Age (y), median (range) | 66 (17-94) |
| Stage at diagnosis∗ | |
| Stage IVA1 | 139 (82.3) |
| Stage IVA2 | 26 (15.4) |
| Stage IVB | 4 (2.4) |
| Coexistent large cell transformation at time of diagnosis with SS | 35 (20.0) |
| Prior history of MF without B2 blood involvement | 48 (27.0) |
| Number of prior lines of therapy for MF, median (range) | 2 (0-9) |
| Number of treatment lines for SS, median (range) | 4 (1-16) |
| Number of lines of systemic therapies for SS, median (range) | 3 (0-14) |
Excludes 9 patients with documented SS but unable to retrospectively verify B stage.